A Mediterranean-like dietary pattern with vitamin D3 (/d) supplements reduced the rate of bone loss in older Europeans with osteoporosis at baseline: results of a 1-y randomized controlled trial.

Plain-language guide to PMID 30007343 (2018): multicenter randomized controlled trial of Vitamin D, K2, Magnesium and Zinc, osteoporosis and bone density.

Key Facts

PMID: 30007343
Journal: The American journal of clinical nutrition
Year: 2018
Study type: Randomized Controlled Trial
Authors: Jennings A et al. (21 authors)
DOI: 10.1093/ajcn/nqy122
Registered trial: NCT01754012

What This Study Did, in Plain Language

What Was Tested

This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc in the context of osteoporosis and bone density.

The aim of this study was to examine the effect of a Mediterranean-like dietary pattern [NU-AGE (New Dietary Strategies Addressing the Specific Needs of the Elderly Population for Healthy Aging in Europe)] on indexes of inflammation with a number of secondary endpoints, including bone mineral density (BMD) and biomarkers of bone and collagen degradation in a 1-y multicenter randomized controlled trial (RCT; NU-AGE) in elderly Europeans.

Who Took Part

PubMed indexes the participants as older adults, both men and women.

Participants in the control group were provided with leaflets on healthy eating available in their country.

How the Study Was Run

The design is described as randomized and multicenter.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

Running at several centres spread the Vitamin D, K2, Magnesium and Zinc study over different clinics and patient groups.

An RCT was undertaken across 5 European centers.

What Was Measured

PubMed files the paper under topics including Amino Acids, Biomarkers, Bone Density, Bone and Bones, Cholecalciferol, Collagen and Diet, Mediterranean.

What This Means in Plain Language

The paper is a randomized and multicenter study of Vitamin D, K2, Magnesium and Zinc in people with osteoporosis and bone density.

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2018 (The American journal of clinical nutrition), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, Osteoporosis and bone density research.

Our Notes on the Compound

Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.